Acute akathisia associated with quetiapine use

Psychosomatics

Volumn 46, Issue 4, 2005, Pages 291-301

  Catalano, Glenn ^a   Grace, John W ^b   Catalano, Maria C ^b   Morales, Miguel J ^b   Cruse, Laura M ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CELECOXIB; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LORAZEPAM; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; STEROID; THIORIDAZINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; DIBENZOTHIAZEPINE DERIVATIVE;

ACUTE DISEASE; ADULT; AKATHISIA; ALLERGY; ANXIETY DISORDER; ARTICLE; ASTHMA; AVASCULAR NECROSIS; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PAIN; PARKINSONISM; PSYCHOPHARMACOTHERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SLEEP DISORDER; TARDIVE DYSKINESIA; TREATMENT OUTCOME; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; FEMALE; HUMANS;

EID: 24044499684     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.46.4.291     Document Type: Review

References (92)

1. Treatment with antipsychotics, in Principles and Practice of Psychopharmacotherapy, 3rd Edition. Edited by Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 83-192
2. Biological therapies2C in Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 9th Edition. Edited by Sadock BJ, Sadock VA. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 974-1150
3. Grimm SW, Dyroff MC: Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997; 25:598-602
4. Seroquel (Quetiapine Fumarate) package insert. Wilmington, Del., AstraZeneca Pharmaceuticals LP, 2004
5. Friedman JH, Wagner RL: Akathisia: the syndrome of motor restlessness. Am Fam Physician 1987; 35:145-149
6. Jauss M, Schroder J, Pantel J, Bachmann S, Gerdsen I, Mundt C: Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry 1998; 31:146-148
7. Barnes TR, McPhillips MA: Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13(suppl 3):49-57
8. Wirshing WC: Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001; 62(suppl 21):15-18
9. Ratey JJ, Salzman C: Recognizing and managing akathisia. Hosp Community Psychiatry 1984; 35:975-977
10. Hirose S: Restlessness of respiration as a manifestation of akathisia: five case reports of respiratory akathisia. J Clin Psychiatry 2000; 61:737-741
11. Fahn S: A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985; 46(4, Pt 2):19-24
12. Teicher MH, Klein DA, Andersen SL, Wallace P: Development of an animal model of fluoxetine akathisia. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19:1305-1319
13. Shear MK, Frances A, Weiden P: Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983; 3:235-236
14. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS: Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry 1996; 37:122-124
15. Barnes TRE, Kidger T: Tardive dyskinesia and problems of assessment, in Current Themes in Psychiatry, vol 2. Edited by Gaind RN, Hudson BL. London, Macmillan, 1978, pp 145-162
16. Boumans CE, de Mooij KJ, Koch PA, van't Hof MA, Zitman FG: Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull 1994; 20:339-344
17. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O: Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology (Berl) 1995; 119:231-238
18. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549-557
19. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61:252-260
20. Prueter C, Habermeyer B, Norra C, Kosinski CM: Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord 2003; 18:712-713
21. Sommer BR: Quetiapine induced extrapyramidal side effects in patients with Parkinson's disease: case report. J Geriatr Psychiatry Neurol 2001; 14:99-100
22. Gill HS, DeVane CL, Risch SC: Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypothesis. J Clin Psychopharmacol 1997; 17:377-389
23. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr: Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50:339-342
24. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
25. Brown TM, Stoudemire A, Fogel BS, Moran MG: Psychopharmacology in the medical patient, in Psychiatric Care of the Medical Patient, 2nd Edition. Edited by Stoudemire A, Fogel BS, Greenberg DB. New York, Oxford University Press, 2000, pp 330-372
26. Collaborative Working Group on Clinical Trial Evaluations: Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998, 59(suppl 12):23-27
27. Safferman AZ, Lieberman JA, Pollack S, Kane JM: Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13:286-287
28. Cohen BM, Keck PE, Satlin A, Cole JO: Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29:1215-1219
29. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
30. Physician's Desk Reference, 58th Edition. Montvale, NJ, Medical Economics Company, 2004
31. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW: Extrapyramidal side-effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995; 118:52-56
32. Hansen L, Wilkinson DG: Drug induced akathisia, suicidal ideation and its treatment in the elderly. Int J Geriatr Psychiatry 2001; 16:230-236
33. Rosebush PI, Kennedy K, Dalton B, Mazurek MF: Protracted akathisia after risperidone withdrawal. Am J Psychiatry 1997; 154:437-438
34. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59:69-75
35. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC: Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999; 156:1374-1379
36. Kopala LC, Good KP, Honer WG: Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997; 17:308-313
37. Fleischhacker WW, Lemmens P, van Baelen B: A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Pharmacopsychiatry 2001; 34:104-110
38. Ho BC, Miller D, Nopoulos P, Andreasen NC: A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60:658-663
39. Ishigooka J, Murasaki M, Miura S, Phase II Study Group: Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Psychiatry Clin Neurosci 2000; 54:467-478
40. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690
41. Keck PE Jr, Reeves KR, Harrigan EP; Ziprasidone Study Group: Ziprasidone in the short-term treatment of patients with schizo-affective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21:27-35
42. Rein W, Coulouvrat C, Dondey-Nouvel L: Safety profile of amisulpride in short- and long-term use. Acta Psychiatr Scand Suppl 2000; 400:23-27
43. Caspi N, Levine J: Treatment of resistant akathisia with ECT: a case report. Isr J Psychiatry Relat Sci 1993; 30:175-178
44. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135-145
45. Muller-Oerlinghausen B, Berghofer A: Antidepressants and suicide risk. J Clin Psychiatry 1999; 60(suppl 2):94-99
46. Bauer M, Hellweg R, Baumgartner A: Fluoxetine-induced akathisia does not reappear after switch to paroxetine. J Clin Psychiatry 1996; 57:593-594
47. Olivera AO: Sertraline and akathisia: spontaneous resolution. Biol Psychiatry 1997; 41:241-242
48. Altshuler LL, Pierre JM, Wirshing WC, Ames D (letter): Sertraline and akathisia. J Clin Psychopharmacol 1994; 14:278-279
49. Opler LA: Sertraline and akathisia (letter). Am J Psychiatry 1994; 151:620-621
50. Poyurovsky M, Meerovich I, Weizman A: Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol 1995; 10:111-114
51. Chong SA, Tan CH: Fluvoxamine and akathisia (letter). J Clin Psychopharmacol 1996; 16:334-335
52. Treatment with antidepressants, in Principles and Practice of Psychopharmacotherapy, 3rd Edition. Edited by Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 215-325
53. Sabaawi M, Richmond DR, Fragala MR: Akathisia in association with nortriptyline therapy (letter). Am Fam Physician 1994; 48:1024, 1026
54. Zubenko GS, Cohen BM, Lipinski JF: Antidepressant-related akathisia. J Clin Psychopharmacol 1987; 7:254-257
55. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P: Tricyclic antidepressant induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7:207-212
56. Eberstein S, Adler LA, Angrist B: Nefazodone and akathisia. Biol Psychiatry 1996; 40:798-799
57. Muthane UB, Prasad BN, Vasanth A, Satishchandra P: Tardive parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate (letter). J Neurol Sci 2000; 176:78-79
58. Shen WW: Alcohol, amoxapine and akathisia (letter). Biol Psychiatry 1984; 19:929-930
59. Shen WW: The management of amoxapine-induced akathisia (letter). Am J Psychiatry 1983; 140:1102-1103
60. Hullett FJ, Levy AB: Amoxapine-induced akathisia (letter). Am J Psychiatry 1983; 140:820
61. Poyurovsky M, Weizman A: Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 2001; 179:4-8
62. Anfinson TJ: Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol Bull 2002; 36:82-93
63. Fawzy FI, Servis ME, Greenberg DB: Oncology and psychooncology, in The American Psychiatric Publishing Textbook of Consultation-Liaison Psychiatry, 2nd Edition. Edited by Wise MG, Rundell JR. Washington, DC, American Psychiatric Publishing, 2002, pp 657-678
64. Lane RM: SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12:192-214
65. Ioannou C, Viswanathan R: Neuroleptic-induced akathisia in an HIV-infected individual (letter). Gen Hosp Psychiatry 1994; 16:57-58
66. Caligiuri MP, Jeste DV, Lacro JP: Antipsychotic induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17:363-384
67. Kurzthaler I, Hummer M, Kohl C, Miller C, Fleischhacker WW: Propranolol treatment of olanzapine induced akathisia (letter). Am J Psychiatry 1997; 154:1316
68. Fleischhacker WW: Propranolol for fluoxetine-induced akathisia (letter). Biol Psychiatry 1991; 30:531-532
69. Sachdev P: Akathisia and Restless Legs. New York, Cambridge University Press, 1995
70. Hirose S, Ashby CR: Intravenous biperiden in akathisia: an open pilot study. Int J Psychiatry Med 2000; 30:185-194
71. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A: Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001; 21:612-615
72. Zubenko GS, Barreira P, Lipinski JF Jr: Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 1984; 4:218-220
73. Factor SA, Friedman JH: The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12:483-496
74. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, O'Brien CF, LeWitt PA, Koller WC: Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13:377-382
75. Levine J, Chengappa KN: Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia (letter). J Clin Psychiatry 1998; 59:195
76. Donlon PT: The therapeutic use of diazepam for akathisia. Psychosomatics 1973; 14:222-225
77. Poyurovsky M, Fuchs C, Weizman A: Low-dose mianserin in treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 1998; 18:253-254
78. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A: Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin: double-blind, placebo-controlled study. Br J Psychiatry 1999; 174:238-242
79. Poyurovsky M, Weizman A: Mirtazapine for neuroleptic-induced akathisia (letter). Am J Psychiatry 2001; 158:819
80. Shulman LM, Singer C, Weiner WJ: Improvement of both tardive dystonia and akathisia after botulinum toxin injection. Neurol 1996; 46:844-845
81. Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A: Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol 2001; 21:248-249
82. Sandyk R: Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam: a case report. Eur Neurol 1985; 24:286-288
83. Shen WW: Akathisia: an overlooked, distressing, but treatable condition. J Nerv Ment Dis 1981; 169:599-600
84. Adityanjee, Schulz SC: Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63(suppl 13):32-38
85. Bellnier TJ: Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm 2002, 59(17 suppl 5):S12-S18
86. McDougle CJ, Kem DL, Posey DJ: Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41:921-927
87. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T: Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:549-553
88. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134-143
89. Al-Samarrai S, Dunn J, Newmark T, Gupta S: Quetiapine for treatment resistant delirium (letter). Psychosomatics 2003; 44:350-351
90. Schwartz TL, Masand PS: The role of atypical antipsychotics in the treatment of delirium. Psychosomatics 2002; 43:171-174
91. Labbate LA, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD) (letter). Can J Psychiatry 2000; 45:667-668
92. Doan RJ: Risperidone for insomnia in PDDs (letter). Can J Psychiatry 1998; 43:1050-1051